Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NPA Slams Study Linking Calcium, Vitamin D Use To Increased Cancer Risk

Executive Summary

Annals of Medicine study finds at least 1,000mg/day calcium supplementation associated with increased risk of cancer, but no association of cancer and high levels of calcium from foods. Natural Products Association says study included an ‘unhealthy’ cohort of patients.

You may also be interested in...



Analysis Finding Low Cardio Benefit From Nutrients Has Critics In Industry, Science

Meta-analysis finds omega-3 and folate can benefit heart-related health, but says association is weak and a combination of calcium and vitamin D may increase risk of stroke. CRN says study is a “coordinated, all-out assault on nutrition” with “major” limitation of omitting epidemiological studies.

AARP-Funded Researchers Say Forget About Supplements To Improve Memory

Studies on supplements and brain health find no benefit in people with normal nutrient levels, says a group of 27 experts brought together by the American Association of Retired Persons. High-quality clinical studies of safety and efficacy of supplements in brain health outcomes are needed, they say.

Bayer Consumer Health Recovery Rides Allergy, Dermatology Brand Sales

Q4 sales in OTC allergy/cold segment, which includes the Claritin allergy and Afrin nasal congestion lines, grew 5% adjusted while dermatology sector with Bepanthen and Canesten skin care brands grew 3.8%. Adjusted for the impact of foreign exchange and portfolio changes, thouhg, consumer unit’s full-year sales were flat.

Topics

UsernamePublicRestriction

Register

RS148739

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel